Equities researchers at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research note issued on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of EVOK opened at $0.49 on Friday. Evoke Pharma has a one year low of $0.41 and a one year high of $2.40. The company has a 50-day simple moving average of $0.57 and a two-hundred day simple moving average of $0.86. The firm has a market capitalization of $4.12 million, a PE ratio of -0.21 and a beta of 0.38.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%. The company had revenue of $1.68 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- MarketBeat Week in Review – 4/29 – 5/3
- Retail Stocks Investing, Explained
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What to Know About Investing in Penny Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
